Events & presentations

Jefferies Global Healthcare Conference

RBC Capital Markets Global Healthcare Conference

REX-8756 is an Oral, First-in-Class Orthosteric STAT6 Inhibitor That Demonstrates Efficacious Potential and Safety Differentiation in a Th2-Mediated Dermatitis Model

Recludix Platform has Unlocked Development of Oral, Reversible Small Molecule Inhibitors of SH2 Domains

Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammation

Novel Inhibitors of the BTK SH2 Domain Selectively and Potently Block BTK Signaling and are Efficacious in Preclinical Models of Chronic Spontaneous Urticaria

STAT6 Program Highlighted in Sanofi R&D Day